Compass Therapeutics Inc. (CMPX) is A Buy on Wall Street on Robust Pipeline Development

Compass Therapeutics Inc. (NASDAQ:CMPX) is a must-buy penny stock to buy now. On November 10, Pipe Sandler analyst Biren Amin reiterated that Compass Therapeutics Inc. (NASDAQ:CMPX) is a Buy and set a $12 price target. The positive stance stems from the company’s announcement that it has made significant progress in developing its clinical pipeline.

HC Wainwright analyst Joseph Pantginis also reiterated a Buy rating on the stock. They set a $24 price target on November 10, buoyed by the development of CTX-10726, a tetravalent antibody that hinders tumor angiogenesis.

While delivering the third-quarter 2025 results, Thomas Schuetz, the Chief Executive Officer, affirmed significant milestones in the development of the company’s drug pipeline. For starters, the company is recording lower mortality rates on a randomized trial of tovecimig in patients with advanced BTC. It is also on track to deliver OS and PFS data in the first quarter of next year.

“These secondary endpoint data will build on the statistically significant primary endpoint of overall response rate we previously reported, and we expect could support our first BLA filing in the second half of 2026. Recent claims-based market research shows ~25,000 patients are diagnosed with BTC annually in the United States alone, and tovecimig could provide hope for the vast majority of patients in the second line who have no approved therapeutic option,” said Schuetz.

Nevertheless, the company posted a net loss of $14.3 million, or $0.08 per share, wider than the net loss of $10.5 million delivered in the same quarter last year. A wider-than-expected net loss is attributed to research and development expenses increasing to $12.8 million from $8.6 million in the same period the previous year.

Compass Therapeutics Inc. (NASDAQ:CMPX) is a clinical-stage biopharmaceutical company focused on developing proprietary antibody-based therapies for cancer. The company’s scientific focus is on the relationship between angiogenesis (the formation of new blood vessels), the immune system, and tumor growth.

While we acknowledge the potential of CMPX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.

Disclosure: None. This article is originally published at Insider Monkey.